Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''

Clinical Significance ◽

Cancer Genomics ◽

Therapeutic Effects ◽

Antibody Treatment ◽

Biomarker Research

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

British Journal of Cancer ◽

10.1038/bjc.2017.308 ◽

2017 ◽

Vol 117 (10) ◽

pp. 1450-1458 ◽

Cited By ~ 31

Author(s):

Eiji Shinozaki ◽

Takayuki Yoshino ◽

Kentaro Yamazaki ◽

Kei Muro ◽

Kensei Yamaguchi ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Monoclonal Antibodies ◽

Clinical Significance ◽

Cancer Genomics ◽

Therapeutic Effects ◽

Antibody Treatment ◽

Biomarker Research

Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’

British Journal of Cancer ◽

10.1038/s41416-018-0012-2 ◽

2018 ◽

Vol 118 (9) ◽

pp. 1276-1277 ◽

Cited By ~ 1

Author(s):

Matthew Dankner ◽

April A. N. Rose

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Monoclonal Antibodies ◽

Clinical Significance ◽

Cancer Genomics ◽

Therapeutic Effects ◽

Antibody Treatment ◽

Biomarker Research

Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.11038 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 11038-11038 ◽

Cited By ~ 1

Author(s):

Satoshi Yuki ◽

Takayuki Yoshino ◽

Katsuya Tsuchihara ◽

Eiji Shinozaki ◽

Kei Muro ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibodies ◽

Cancer Patients ◽

Cancer Genomics ◽

Clinical Impact ◽

Mutational Status ◽

Biomarker Research ◽

Colorectal Cancer Patients ◽

Egfr Antibody

Molecular Markers for the Prediction of Anti-EGFR Monoclonal Antibody Treatment Efficacy in Metastatic Colorectal Cancer

Journal of Cancer Therapy ◽

10.4236/jct.2011.25090 ◽

2011 ◽

Vol 02 (05) ◽

pp. 675-682 ◽

Cited By ~ 3

Author(s):

Cheng-Bo Han ◽

Jie-Tao Ma ◽

Fan Li ◽

Hua-Wei Zou

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Molecular Markers ◽

Treatment Efficacy ◽

Antibody Treatment ◽

Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

World Journal of Gastroenterology ◽

10.3748/wjg.v16.i10.1177 ◽

2010 ◽

Vol 16 (10) ◽

pp. 1177 ◽

Cited By ~ 16

Author(s):

Zacharenia Saridaki

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Mechanisms Of Resistance ◽

Antibody Treatment ◽

A Mathematical Model for Assessing KRAS Mutation Effect on Monoclonal Antibody Treatment of Colorectal Cancer

Software Engineering and Formal Methods - Lecture Notes in Computer Science ◽

10.1007/978-3-319-15201-1_16 ◽

2015 ◽

pp. 243-258

Author(s):

Sheema Sameen ◽

Roberto Barbuti ◽

Paolo Milazzo ◽

Antonio Cerone

Keyword(s):

Colorectal Cancer ◽

Mathematical Model ◽

Monoclonal Antibody ◽

Kras Mutation ◽

Antibody Treatment ◽

Management of Skin Toxicity Associated with EGFR-targeted Monoclonal Antibody Treatment for Advanced Colorectal Cancer: A Single Center Experience

Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) ◽

10.4030/jjcs.38.279 ◽

2013 ◽

Vol 38 (2) ◽

pp. 279-285

Author(s):

Atsuko Fukazawa ◽

Akihiro Uno ◽

Osamu Jindo ◽

Keigo Matsumoto ◽

Hideto Ochiai ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Advanced Colorectal Cancer ◽

Skin Toxicity ◽

Single Center ◽

Antibody Treatment ◽

Single Center Experience ◽

BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis

Chinese Medical Sciences Journal ◽

10.1016/s1001-9294(14)60070-5 ◽

2014 ◽

Vol 29 (4) ◽

pp. 197-203 ◽

Cited By ~ 9

Author(s):

Qi Wang ◽

Wei-guo Hu ◽

Qi-bin Song ◽

Jia Wei

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibodies ◽

Predictive Factor ◽

Meta Analysis ◽

Braf V600e Mutation ◽

Braf V600e ◽

Therapeutic Effects

Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-013-2211-0 ◽

2013 ◽

Vol 72 (2) ◽

pp. 397-403 ◽

Cited By ~ 11

Author(s):

David Tougeron ◽

Ulrich Cortes ◽

Aurélie Ferru ◽

Claire Villalva ◽

Christine Silvain ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Antibody Treatment ◽

Kras Mutations ◽

Epidermal Growth

P-255 The clinical significance of the gut microbiota in RAS wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies in combination with chemotherapy – preliminary results

Annals of Oncology ◽

10.1016/j.annonc.2021.05.309 ◽

2021 ◽

Vol 32 ◽

pp. S185

Author(s):

T. Lewandowski ◽

P. Stelmasiak ◽

J. Stefańska ◽

R. Wolinowska ◽

B. Bobrowska ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibodies ◽

Gut Microbiota ◽

Cancer Patients ◽

Clinical Significance ◽

Wild Type ◽

Preliminary Results ◽

Colorectal Cancer Patients